Insider Selling: Twist Bioscience (NASDAQ:TWST) CFO Sells $226,297.67 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,399 shares of the stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer owned 110,276 shares in the company, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

• On Friday, April 17th, Adam Laponis sold 4,000 shares of Twist Bioscience stock. The stock was sold at an average price of $60.00, for a total transaction of $240,000.00.
• On Tuesday, April 14th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $55.00, for a total transaction of $165,000.00.

Twist Bioscience Stock Up 0.1%

TWST stock opened at $92.61 on Thursday. The firm’s fifty day simple moving average is $76.35 and its 200-day simple moving average is $57.35. The company has a market capitalization of $5.77 billion, a P/E ratio of -69.63 and a beta of 2.11. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $105.47.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million for the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the business earned ($0.66) EPS. As a group, equities research analysts forecast that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently bought and sold shares of the business. ARK Investment Management LLC increased its position in shares of Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after buying an additional 832,687 shares in the last quarter. William Blair Investment Management LLC raised its stake in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock worth $188,874,000 after buying an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. lifted its position in shares of Twist Bioscience by 31.7% during the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after buying an additional 1,295,672 shares in the last quarter. State Street Corp lifted its position in shares of Twist Bioscience by 17.4% during the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after buying an additional 538,755 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after acquiring an additional 1,080,722 shares during the period.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Barclays upped their target price on Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Piper Sandler began coverage on Twist Bioscience in a research report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price target for the company. Guggenheim boosted their price target on Twist Bioscience from $60.00 to $107.00 and gave the company a “buy” rating in a report on Monday, June 29th. Robert W. Baird upped their price objective on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Finally, Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective on the stock. in a research report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.